Nature Search

Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies

Corina Amor
Judith Feucht
Scott W. Lowe
Amendments and Corrections21 Feb 2024
Nature

Volume: 627, P: E9
HLA-independent T cell receptors for targeting tumors with low antigen density

HLA-independent T cell receptors, in which the heavy and light chains of a chimeric antigen receptor are incorporated into the endogenous T cell receptor locus, are more effective than CD28-based chimeric antigen receptors at targeting tumors with low antigen expression.

Jorge Mansilla-Soto
Justin Eyquem
Michel Sadelain
Research13 Jan 2022
Nature Medicine

Volume: 28, P: 345-352
Senolytic CAR T cells reverse senescence-associated pathologies

Chimeric antigen receptor (CAR) T cells targeting uPAR, a cell-surface protein that is upregulated on senescent cells, eliminate senescent cells in vitro and in vivo and reduce liver fibrosis in mice.

Corina Amor
Judith Feucht
Scott W. Lowe
Research17 Jun 2020
Nature

Volume: 583, P: 127-132
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

Chimeric antigen receptors (CARs) promote antigen loss in tumour cells by trogocytosis, which results in T cell fratricide killing and exhaustion but can be counteracted by cooperative killing and combinatorial targeting.

Mohamad Hamieh
Anton Dobrin
Michel Sadelain
Research27 Mar 2019
Nature

Volume: 568, P: 112-116
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Blocking IL-1 and iNOS prevents CAR T cell–induced cytokine release syndrome.

Theodoros Giavridis
Sjoukje J. C. van der Stegen
Michel Sadelain
Research28 May 2018
Nature Medicine

Volume: 24, P: 731-738
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Introducing chimeric antigen receptors into the endogenous T-cell receptor locus reduces tonic signalling, averts accelerated T-cell differentiation and delays T-cell exhaustion, leading to enhanced function and anti-tumour efficacy compared to random integrations.

Justin Eyquem
Jorge Mansilla-Soto
Michel Sadelain
Research22 Feb 2017
Nature

Volume: 543, P: 113-117
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

This Review discusses our current understanding of the pathophysiological mechanisms of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome associated with chimeric antigen receptor (CAR) T cell therapies, and how this might be used for the prevention or management of these toxicities.

Emma C. Morris
Sattva S. Neelapu
Michel Sadelain
Reviews17 May 2021
Nature Reviews Immunology

Volume: 22, P: 85-96

Search

Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies

HLA-independent T cell receptors for targeting tumors with low antigen density

Senolytic CAR T cells reverse senescence-associated pathologies

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Search

Quick links

Search

Filter By:

Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies

HLA-independent T cell receptors for targeting tumors with low antigen density

Senolytic CAR T cells reverse senescence-associated pathologies

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Search

Quick links